Enhanced Therapeutic Efficacy of the Nanoscale Fluoropyrimidine Polymer CF10 in a Rat Colorectal Cancer Liver Metastasis Model

Charles Chidi Okechukwu,Xue Ma,Naresh Sah,Chinnadurai Mani,Komaraiah Palle,William H. Gmeiner

DOI: https://doi.org/10.3390/cancers16071360

2024-03-31

Cancers

Abstract:Combination chemotherapy regimens that include fluoropyrimidine (FP) drugs, e.g., 5-fluorouracil (5-FU), are central to the treatment of colorectal cancer liver metastases (CRLMs), a major cause of cancer mortality. We tested a second-generation FP polymer, CF10, in a CC531/WAGRij syngeneic orthotopic rat model of liver metastasis to determine if CF10 improved response relative to 5-FU. CF10 displayed increased potency relative to 5-FU in CC531 rat colorectal cancer cells based on clonogenic assay results and caused increased apoptosis, as shown using a live/dead assay. The increased potency of CF10 to CC531 cells was associated with increased replication stress, as assessed by Western blot for biomarkers of ATR/Chk1 and ATM/Chk2 pathway activation. CF10 dosed to deliver equivalent FP content as an established dose of 5-FU in rats (50 mg/kg) did not cause weight loss in WAGRij rats even when combined with ethynyl uracil (EU), an inhibitor of dihydropyrimidine dehydrogenase, the enzyme primarily responsible for 5-FU degradation in the liver. In contrast, 5-FU caused significant weight loss that was exacerbated in combination with EU. Importantly, CF10 was significantly more effective than 5-FU at inhibiting tumor progression (~90% reduction) in the CC531/WAG/Rij CRLM model. Our results reveal strong potential for CF10 to be used for CRLM treatment.

oncology

What problem does this paper attempt to address?

The main problem that this paper attempts to solve is to evaluate whether the new nanoscale fluoropyrimidine polymer CF10 has a better therapeutic effect in the rat colorectal cancer liver metastasis model than the traditional chemotherapeutic drug 5 - fluorouracil (5 - FU). Specifically, the study aims to verify whether CF10 can show better efficacy in the following aspects:

1. **Cytotoxicity**: Through the colony - forming assay and live/dead cell staining experiment, evaluate the cytotoxicity of CF10 relative to 5 - FU on CC531 rat colon cancer cells and the ability to induce apoptosis.
2. **Replication stress and DNA damage**: Through Western blot analysis, detect whether CF10 can more effectively activate replication - stress - related biomarkers (such as pRPA, pChk1) and cause DNA double - strand breaks (DSBs).
3. **In - vivo tolerance**: Test the tolerance of CF10 in WAG/Rij rats, especially whether it can avoid the weight loss and other systemic toxicities caused by 5 - FU.
4. **Antitumor activity**: In the rat colorectal cancer liver metastasis model, compare the antitumor activities of CF10 and 5 - FU, especially the efficacy at the same dose.

### Main research background

Colorectal cancer (CRC) is the second leading cause of cancer - related deaths worldwide, and liver metastasis is the most common fatal factor. Although 5 - FU and its combined chemotherapy regimens (such as FOLFOX and FOLFIRI) have been widely used to treat colorectal cancer liver metastasis (CRLM), these therapies usually cannot significantly prolong the survival time of patients and are often accompanied by serious side effects. Therefore, it is of great significance to develop new chemotherapeutic drugs that are more effective and less toxic.

### Research methods

The researchers used the CC531/WAG/Rij syngeneic orthotopic rat model to simulate colorectal cancer liver metastasis and verified the efficacy of CF10 through the following experiments:

1. **In - vitro experiments**:
- Use the modified colony - forming assay to evaluate the cytotoxicity of CF10 and 5 - FU on CC531 cells.
- Analyze the apoptosis induced by CF10 through flow cytometry.
- Detect the changes in replication - stress - and DNA - damage - related proteins caused by CF10 using Western blot.

2. **In - vivo experiments**:
- Conduct tolerance tests of CF10 and 5 - FU in WAG/Rij rats and observe weight changes and other toxic reactions.
- Monitor tumor progression through fluorescence imaging and compare the antitumor effects of CF10 and 5 - FU.

### Main findings

1. **Cytotoxicity**: CF10 shows higher cytotoxicity and stronger apoptosis - inducing ability in CC531 cells than 5 - FU.
2. **Replication stress and DNA damage**: CF10 can more effectively activate replication - stress - related pathways (such as ATR/Chk1 and ATM/Chk2) and cause DNA double - strand breaks.
3. **In - vivo tolerance**: CF10 shows good tolerance in rats and does not cause significant weight loss or other systemic toxicities.
4. **Antitumor activity**: At the same dose, CF10 significantly inhibits tumor progression in the rat colorectal cancer liver metastasis model, and the effect is better than that of 5 - FU.

### Conclusion

The study shows that CF10, as a new fluoropyrimidine polymer, shows better therapeutic effects than 5 - FU in the rat colorectal cancer liver metastasis model, with higher cytotoxicity and antitumor activity, and better tolerance at the same time. These results provide a strong basis for CF10 to enter clinical trials and are expected to improve the treatment effect of patients with colorectal cancer liver metastasis.